Dr. Reddy's Laboratories is currently trading at Rs. 5468.00, up by 16.65 points or 0.31% from its previous closing of Rs. 5451.35 on the BSE.
The scrip opened at Rs. 5440.00 and has touched a high and low of Rs. 5480.00 and Rs. 5425.65 respectively. So far 1267 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5986.20 on 24-Aug-2023 and a 52 week low of Rs. 4176.85 on 25-Jan-2023.
Last one week high and low of the scrip stood at Rs. 5499.55 and Rs. 5322.60 respectively. The current market cap of the company is Rs. 90704.13 crore.
The promoters holding in the company stood at 26.66%, while Institutions and Non-Institutions held 49.23% and 10.09% respectively.
Dr. Reddy's Laboratories has acquired 26% of the paid up equity share capital of O2 Renewable Energy IX (SPV) in the first tranche, in accordance with terms and conditions of the Security Subscription and Shareholders’ Agreement (SSHA). The object of acquisition is to access renewable power through solar and wind power plants through (Inter-State Transmission System) ISTS under captive structure.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1933.10 |
| Dr. Reddys Labs. | 1210.85 |
| Cipla | 1418.40 |
| Lupin | 2442.10 |
| Zydus Lifesciences | 1142.75 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: